No Detail Found!

Drugs being tested against COVID-19 to slow down its spread and find effective treatment: A systematic review.

Author(s)
Arsalan Rasheed Department of Zoology, Abdul Wali Khan University Mardan, Mardan-Pakistan.
Malaika Noor Department of Zoology, Kohat University of Science and Technology, Kohat-Pakistan.
Tahir Usman College of Veterinary Sciences and Animal Husbandry, Abdul Wali Khan University Mardan, Mardan-Pakistan.
Rizwana Bilqees Department of Botany, University of Chitral, Chitral-Pakistan.
Muhammad Afnan Khyber Medical Institute of Medical Sciences Kohat, Kohat-Pakistan.
Saira Gul College of Veterinary Sciences and Animal Husbandry, Abdul Wali Khan University Mardan, Mardan-Pakistan.
Naimat Ullah Khan College of Veterinary Sciences and Animal Husbandry, Abdul Wali Khan University Mardan, Mardan-Pakistan.
Saadullah Khattak Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng-China.
Irfan Khattak College of Veterinary Sciences and Animal Husbandry, Abdul Wali Khan University Mardan, Mardan-Pakistan.
Assar Ali Shah Tropical Feed Resources Research and Development Center, Department of Animal Science, Khon Kaen University, Khon Kaen-Thailand.
Abstract
Background: The SARS-CoV-2's spread from continent to the continent has resulted in an increased number of mutations in the viral gene encoding proteins. As a result, mutations in target proteins provide a significant challenge in creating antiviral drugs and vaccines. The present review discussed the COVID-19 epidemiology and the effects of drugs being tested against COVID-19/SARS-CoV-2. Dosage of these drugs along with associated challenges was also discussed. Methodology: Systematic review was conducted after a thorough search in the PubMed, NIH, Elsevier, Scopus, Web of Science, Science direct and Google Scholar database. 45 studies on drugs associated with COVID-19 fulfilled the inclusion criteria and were selected for this review. Results: Food and Drug Administration (FDA) only accepted the Remdesivir drug against SARS-CoV-2, as the hospitalized patients recovered very quickly by taking it. Antiviral EIDD-2801 has been found to make the SARS-CoV-2 unable to infect cells by causing genetic modifications in the virus RNA. Similarly, Nitazoxanide appeared beneficial against SARS-CoV-2 in a primary intervention and severe conditions (including pregnancy) without undesirable effects on the newborns. Children with mild cases can be handled solely by proper caring. Conclusion: Although Remdesivir and Dexamethasone are recommended in severe cases, clinical trials are ongoing to investigate other possible therapies like MAb and Convalescent Plasma antibodies for COVID19. Older drugs (usually used to treat other conditions) are also under-tested by researchers to see if they are effective for COVID-19. Further tests are essential to validate whether any of the mentioned above possible therapies would be helpful for COVID-19 treatment.
Publication Details
Page(s) 255-272
Published Journal: International Journal of Endorsing Health Science Research, Volume: 10, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
SARS-CoV-2, COVID-19, COVID-19, Treatment, Clinical science, Coronavirus, Remdesivir, drugs
0

Citations

0

Downloads

68

Views